Belldegrun Arie

Belldegrun Arie is listed in filings as Director at UroGen Pharma Ltd.. This profile follows SEC Form 4 activity through Jun 24, 2026, including 16 public disclosures. Recent filings connect the profile to UroGen Pharma Ltd. (URGN), Kronos Bio, Inc. (KRON), Ginkgo Bioworks Holdings, Inc. (DNA), and Allogene Therapeutics, Inc. (ALLO). The current snapshot covers public activity from Jun 14, 2024 to Jun 24, 2026. Reported amounts are shown as $699.8K to $390.0K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.